1 condition in the Repatriation Medical Authority's Statements of Principles list malignant neoplasm of the bladder as a factor. If DVA has accepted your malignant neoplasm of the bladder, each of these has a documented pathway to a further claim.
Some Statement of Principles factors are not about service at all — they name another condition. Where DVA has already accepted your malignant neoplasm of the bladder, and another condition's SoP lists malignant neoplasm of the bladder as a factor, that part of the next claim is already established on your file. How a secondary claim works, in full →
Quoted from the instrument. A pathway existing is not the same as a claim succeeding — each factor carries thresholds your record has to satisfy.
RH No. 75 of 2018 · BoP No. 76 of 2018
Reasonable Hypothesis — factor (4): “having intravesical BCG therapy for malignant neoplasm of the bladder or intradermal BCG therapy for a malignant neoplasm within the 30 days before the clinical onset of reactive arthritis” [clinical onset]
Balance of Probabilities — factor (4): “having intravesical BCG therapy for malignant neoplasm of the bladder or intradermal BCG therapy for a malignant neoplasm within the 30 days before the clinical onset of reactive arthritis” [clinical onset]
Note: BCG therapy is defined in the Schedule 1 - Dictionary.
If any of these is also on your file, it reaches some of the same conditions malignant neoplasm of the bladder does.
A claim is tested against the definition first. If the diagnosis on your file does not meet this wording, the factors below never get reached — so it is worth checking that what your doctor wrote matches what the instrument requires.
Malignant neoplasm of the bladder, for the purposes of the Statement of Principles, for the purposes of this Statement of Principles, malignant neoplasm of the bladder: (a) means a primary malignant neoplasm arising from the epithelial cells of the urinary bladder, including the ureteric orifice and the urethral orifice of the bladder; and (b) includes urothelial carcinoma (also known as transitional cell carcinoma), squamous cell carcinoma, adenocarcinoma, small cell carcinoma and carcinoma in situ; and (c) excludes soft tissue sarcoma, carcinoid tumour, non-Hodgkin lymphoma and Hodgkin's lymphoma. (3) While malignant neoplasm of the bladder attracts ICD-10-AM code C67 or D09.0, in applying this Statement of Principles the meaning of malignant neoplasm of the bladder is that given in subsection (2). (4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.
Note the exclusion. This instrument expressly excludes soft tissue sarcoma, carcinoid tumour, non-Hodgkin lymphoma and Hodgkin's lymphoma. A diagnosis of that is not a diagnosis of malignant neoplasm of the bladder, and a claim framed the wrong way fails on the definition before any factor is considered.
Aggravation-only factors. In this instrument, subsections 9(28) apply only to material contribution to, or aggravation of, malignant neoplasm of the bladder where it was already present before or during service. If service caused malignant neoplasm of the bladder outright, those factors are not available to you.
RH No. 83 of 2019
The Statement of Principles for malignant neoplasm of the bladder names 3 other conditions among its own factors. If any of these is already accepted on your file, it may be the factor that carries a malignant neoplasm of the bladder claim — quoted here from the instrument.
Reasonable Hypothesis — factor (14): “having renal stone disease or a bladder stone at least five years before the clinical onset of malignant neoplasm of the bladder” [clinical onset]
Reasonable Hypothesis — factor (20): “having diabetes mellitus for at least five years before the clinical onset of malignant neoplasm of the bladder” [clinical onset]
Reasonable Hypothesis — factor (21): “having benign prostatic hyperplasia at least five years before the clinical onset of malignant neoplasm of the bladder” [clinical onset]

Reviewed by Dr Thomas Perkins
Founding doctor, Veterans Health Centre · former RAAF aviation medical officer · 13 years working exclusively with ADF members and veterans. Full profile →
Contact us for more information.